Dr. Reddy’s gets inspection report from USFDA for Srikakulam-based API plant
Dr. Reddy’s Laboratories on Friday (September 6, 2024) said it has received the establishment inspection report (EIR) from the U.S. health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The U.S. Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection…
Read More “Dr. Reddy’s gets inspection report from USFDA for Srikakulam-based API plant” »